In other tumor types, such as melanoma, colorectal, and lung cancer, activating BRAF mutations occur mostly in a non-overlapping distribution with other genes that converge on activation of ERK signaling pathways (i.e., KRAS, NRAS, NF1, EGFR). This evidence concerns the gene KRAS and lung cancer.